Novo Nordisk Arms Wegovy to Be a Triple Threat

Key PointsNovo Nordisk has seen unprecedented success with its GLP-1 drugs Ozempic and Wegovy for Type 2 diabetes and obesity, respectively.Wegovy was used in a study of obese Type 2 diabetes patients with heart failure with preserved ejection fraction (HFpEF) against a placebo, resulting in conclusive improvements that met primary endpoints.Novo Nordisk seeks to expand its indications to include cardiovascular diseases and possibly neurological disorders.5 stocks we like better than Novo Nordisk A/SOzempic ...